To join this case, fill out the form below
By clicking on the Submit button below, I acknowledge that I have read the Retainer Agreement and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
By clicking on the Submit button below, I acknowledge that I have read the Derivative Retention Letter and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
A signed Retainer Agreement will be sent to your email shortly.
Oops! Something went wrong while submitting the form.

ImmunoGen, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of ImmunoGen, Inc. (“ImmunoGen” or the “Company”) (NASDAQ: IMGN), in connection with its proposed acquisition by AbbVie Inc. (NYSE: ABBV).  Under the merger agreement, Company shareholders will receive $31.26 per share.

Weiss Law is investigating whether (i) the ImmunoGen board acted in the best interests of Company shareholders in agreeing to the merger, (ii) the $31.26 merger consideration adequately compensates ImmunoGen shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com